跳到正文
Pharma Jonpi . / 1.1 / .· @pharma_jonpi · X·· 2 天前评分70

DELLPHI-305

正文 · 机器翻译

小细胞肺癌一线维持治疗

D日,明天在 #ESMO26

DELLPHI-305 ( TARLATAMAB+DURVALUMAB)

对比 IMFORTE
( LURBINECTEDIN+ATEZOLIZUMAB )

我们将看到 OS /PFS /HR

差异化优势:TARLATAMAB 可进入大脑

“IMFORTE 不行”

https://www.amgen.com/newsroom/press-releases/2026/09/imdelltra-in-combination-with-imfinzi-demonstrated-landmark-improvement-in-overall-survival-in-first-line-extensive-stage-small-cell-lung-cancer
#pharmamar @Amgen

118 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要
LBA3按 Presidential Symposium I 对上

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

来源:Pharma Jonpi . / 1.1 / . · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org